Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome

被引:26
|
作者
Goswami, Meghali [1 ]
Duvic, Madeleine [1 ]
Dougherty, Alexis [1 ]
Ni, Xiao [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
关键词
c-myc; mycosis fungoides; p53; Sezary syndrome; Twist; T-CELL LYMPHOMA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; UP-REGULATION; INTERNATIONAL-SOCIETY; CUTANEOUS-LYMPHOMAS; PROGNOSTIC-FACTORS; DOWN-REGULATION; CANCER; STAT3;
D O I
10.1111/j.1600-0560.2012.01883.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The mechanisms of tumor progression in mycosis fungoides (MF) and Sezary syndrome (SS) are poorly understood. Twist, a transcription factor, is thought to promote solid tumor progression by blocking p53 and inhibiting c-myc-induced apoptosis. Whether Twist expression is correlated to MF/SS stages remains unknown. Methods: Twist, c-myc and p53 proteins in 68 MF/SS lesions across all T stages were examined by immunohistochemistry, and mRNA levels in peripheral blood CD4+ T-cells from SS patients were measured by real-time quantitative polymerase chain reaction. Results: Positive staining for Twist was found in 12.5% (2/16) of T1 and 33.3% (7/21) of T2 early stage patches/plaques compared to 50.0% (9/18) of T3 tumors and 84.6% (11/13) of T4 erythroderma. Most T4 erythroderma were positive for Twist in dermal lymphocytes, with the strongest staining. Positive staining for c-myc was higher in T3/T4 lesions (29/31, 93.5%) than T1/T2 lesions (25/37, 67.6%, p < 0.05), with strongest staining in T3 tumors. Aberrant p53 expression was more common in T3/T4 lesions (8/31, 25.8%) than in T1/T2 lesions (2/37, 5.4%, p < 0.05). Twist mRNA was detected in all CD4+ T cells from SS patients but not in normal donors. Conclusions: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 50 条
  • [41] Romidepsin in combination with low-dose methotrexate in advanced-stage mycosis fungoides and Sezary syndrome
    Cieza-Diaz, Deysy Elizabeth
    Machan, Salma
    Prieto-Torres, Lucia
    Requena, Luis
    Cordoba, Raul
    DERMATOLOGIC THERAPY, 2021, 34 (03)
  • [42] Multidisciplinary Management of Mycosis Fungoides/Sezary Syndrome
    Berg, Sara
    Villasenor-Park, Jennifer
    Haun, Paul
    Kim, Ellen J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (03) : 234 - 243
  • [43] Diminished CD3 expression in Sezary syndrome/mycosis fungoides
    Edelman, JM
    Meyerson, HJ
    LABORATORY INVESTIGATION, 1999, 79 (01) : 136A - 136A
  • [44] Bcl-3 and RelB expression in mycosis fungoides and Sezary syndrome
    Dobbeling, U.
    Qin, J.
    Kamarachev, J.
    Dummer, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S91 - S91
  • [45] Bexarotene therapy for mycosis fungoides and Sezary syndrome
    Abbott, R. A.
    Whittaker, S. J.
    Morris, S. L.
    Russell-Jones, R.
    Hung, T.
    Bashir, S. J.
    Scarisbrick, J. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (06) : 1299 - 1307
  • [46] The biomarker landscape in mycosis fungoides and Sezary syndrome
    Dulmage, Brittany
    Geskin, Larisa
    Guitart, Joan
    Akilov, Oleg E.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (08) : 668 - 676
  • [47] Differences in the miRNA expression profiles of erythrodermic mycosis fungoides and Sezary syndrome
    Rittig, Anne Hald
    Lindahl, Lise Maria
    Johansen, Claus
    Odum, Niels
    Iversen, Lars
    Litman, Thomas
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S3 - S4
  • [48] Is smoking associated with mycosis fungoides and Sezary syndrome?
    Chang, H. -C.
    Tsai, T. -Y.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (05) : E381 - E384
  • [49] Mycosis fungoides and Sezary syndrome - Review and outlook
    Latzka, Johanna
    Trautinger, Franz
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (04): : 391 - 392
  • [50] MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
    GISSELBRECHT, C
    DUBERTRET, L
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1993, 35 (01): : 73 - 75